Biotech and Pharmaceuticals
Healthy Returns: What activist Starboard’s $1 billion stake means for Pfizer
Jakub Porzycki | Nurphoto | Getty Images A version of this article first appeared in CNBC’s Healthy Returns newsletter, which brings the latest health-care news straight to your inbox. Subscribe here to receive future editions. Happy Tuesday! Pfizer‘s troubles may finally be coming to a head. Former executives of the pharmaceutical giant are backing a […]
Read More
Supreme Court rejects Martin Shkreli fine appeal
Former drug company executive Martin Shkreli and his lead attorney Benjamin Brafman arrive at U.S. District Court for the fourth day of jury deliberations in his securities fraud trial in the Brooklyn borough of New York City, U.S., August 3, 2017. Amr Alfiky | Reuters The Supreme Court on Monday rejected a bid by notorious […]
Read More
CVS is under pressure and considering a break up. Here’s why that could be risky
A sign outside of a CVS pharmacy store on February 07, 2024 in Miami, Florida. Joe Raedle | Getty Images It’s time for a wellness check at CVS Health. Shares of the company are down more than 20% this year as it grapples with higher-than-expected medical costs in its insurance unit and pharmacy reimbursement pressure, […]
Read More
Healthy Returns: Pfizer pulls sickle cell disease drug from markets – here’s why it matters
Kena Betancur | Corbis News | Getty Images A version of this article first appeared in CNBC’s Healthy Returns newsletter, which brings the latest health-care news straight to your inbox. Subscribe here to receive future editions. Hello and happy Tuesday! Today, we’re unpacking a shocking move from Pfizer. The pharmaceutical giant last week announced it […]
Read More
FDA approves Bristol Myers Squibb’s schizophrenia drug, the first new type of treatment in decades
Bristol Myers Squibb’s Cobenfy drug Courtesy: Bristol Myers Squibb The Food and Drug Administration on Thursday approved Bristol Myers Squibb‘s highly anticipated schizophrenia drug Cobenfy, the first novel type of treatment for the debilitating, chronic mental disorder in more than seven decades. Schizophrenia affects how a person thinks, feels and behaves, and can cause paranoia, […]
Read More
Novo Nordisk’s diabetes drug Ozempic may lower the risk of opioid overdoses, study says
A box of Ozempic made by Novo Nordisk is seen at a pharmacy in London, Britain March 8, 2024. Hollie Adams | Reuters Novo Nordisk‘s blockbuster diabetes drug Ozempic may decrease the risk of opioid overdoses in certain patients, demonstrating its potential as an alternative treatment for opioid use disorder, according to a new study […]
Read More
Healthy Returns: Weight loss drug Wegovy could face Medicare price negotiations next
Boxes of Ozempic and Wegovy made by Novo Nordisk are seen at a pharmacy in London, Britain March 8, 2024. Hollie Adams | Reuters A version of this article first appeared in CNBC’s Healthy Returns newsletter, which brings the latest health-care news straight to your inbox. Subscribe here to receive future editions. Good afternoon! Wegovy, […]
Read More
Novo Nordisk CEO to testify at Senate hearing over high weight loss drug prices
Lars Fruergaard Jørgensen, CEO of Novo Nordisk, speaks during an interview in New York on Aug. 10, 2022. Christopher Goodney | Bloomberg | Getty Images Novo Nordisk‘s top executive is slated to face a Senate grilling on Tuesday over the high prices of the company’s weight loss drug Wegovy and diabetes treatment Ozempic, as demand […]
Read More
FTC sues drug middlemen for allegedly inflating insulin prices
The Federal Trade Commission on Friday sued three large U.S. health companies that negotiate insulin prices, arguing the drug middlemen use practices that boost their profits while “artificially” inflating costs for patients. The suit targets the three biggest so-called pharmacy benefit managers, UnitedHealth Group’s Optum Rx, CVS Health’s Caremark and Cigna’s Express Scripts. All are […]
Read More
Novartis not joining the ‘frenzy’ of weight loss drugs, CEO says
The CEO of Novartis said Wednesday that the Swiss pharmaceutical giant does not plan to enter into the “frenzy” of weight loss drugs, preferring instead to focus on areas where it can build a “unique position.” Speaking to CNBC, Vas Narasimhan said that the company was researching treatments that deal with the secondary effects of […]
Read More